2025 VBEF Future Healthcare & Pharma Top 100 Summit: Where 1000+ Capital Buyers Meet 2000+ Innovative Assets

Since the beginning of 2025, two trends have become evident: listed companies have led the recovery in financial performance, and investment and financing activities in the primary market have significantly increased; a large number of high-quality innovative assets and projects in the healthcare and pharmaceutical sectors are going global, accelerating their integration into the global value ecosystem.

Looking Beyond Phenomena to the Essence—This may reflect the cumulative strength built up over decades of healthcare infrastructure development in China, the continuous iteration of evolving demands from both patients and providers, and the deepening advancement of medical technological capabilities. Amid global shifts characterized by an aging population and the restructuring of geopolitical landscapes, high-quality assets in medical and pharmaceutical innovation that integrate composite values such as efficiency and innovation are becoming essential choices for international capital allocation.

This May, an industrial reshuffling involving high-quality assets in China’s medical and pharmaceutical innovation sector is set to unfold.May 9–10, the 2025 VBEF Top 100 Future Healthcare & Pharma Exhibition (VBEF) will be held at the Suzhou International Expo Center, by adopting the tripartite model of “forum + exhibition + trading,” it facilitates deep connections between high-quality assets and global capital, local industrial chains, and end-user medical institutions, thereby helping China’s innovative, high-quality healthcare and pharmaceutical assets make the leap from “innovation capability” to “productive capacity.”

The two-day main forum will showcase the latest insights from key participants in China’s healthcare and pharmaceutical industry. Academicians of the Chinese Academy of Sciences, discipline leaders, representatives from multinational corporations, executives from leading and high-growth companies, as well as frontline investors, will address the industry’s “tipping point.” They will interpret macro-level trends, identify directions for industrial innovation, learn from exemplary corporate solutions, and explore strategies for global expansion.Friends are welcome to register and participate.

(Information statistics as of April 1; agenda will be updated gradually)

High-Density Dialogue Among Leaders from Government, Industry, Academia, Research, Healthcare, and Investment: Anchoring the Development Trends of China’s High-Quality Assets

How high is the caliber of guests and the density of information at the VBEF Main Forum? Both the macro and micro aspects of China’s healthcare and pharmaceutical industry are integrated into this conference.

On the 9th, the main forum will examine global trends and industrial innovation from a macro perspective throughout the day.

Gao Guobiao, former Party Secretary and Deputy Director of the Center for Medical Device Technical Evaluation under the former China Food and Drug Administration, and Li Datao, founder of VCBeat, will deliver opening remarks at the conference.

On the academic and research front, distinguished guests—including an Academician of the Chinese Academy of Sciences, the former Director of the Department of System Reform under the National Health Commission, the Director of the Aging Development Strategy Research Center at Nankai University, the founding Editor-in-Chief of the scientific journal Science Robotics, and the founder of the academic journal The Innovation—were present to share their insights on global trends in the healthcare and pharmaceutical industries, focusing on technological innovation and healthcare systems.

On the industry investment front, private healthcare systems represented by Aier Eye Hospital, Gushengtang, and United Liage; high-tech companies represented by United Imaging Intelligence and DAMO Academy; and investment perspectives represented by Sherpa Capital will together ignite a thought-provoking storm around premium assets in the healthcare and pharmaceutical sectors.

Throughout the 10th, focusing on individual development, we will gather high-quality assets and buyers to achieve value multiplication for China's innovative medical and pharmaceutical assets.

JLL Life Sciences Real Estate crosses industry boundaries, bringing together high-quality buyers—including state-owned investment firms, venture capital (VC), corporate venture capital (CVC), and industrial investors—represented by Legend Star, Junlian Capital, Medtronic China Fund, Yuanhe Origin, Wuxi Innovation Investment Group, Huagai Medical Investment, and Pivotal bioVenture, who will disclose their investment methodologies; meanwhile, high-quality assets represented by JD Health, Knowledge Matrix, Shanwaishan, and Topcare Medical will share their corporate development strategies.

Globalization was another key theme of the forum. Led by Zhang Yuhui, a member of the Party Committee of the Hainan Provincial Health Commission, representatives from the International Cooperation Department of the China Medical Equipment Association and the International Department of the United Nations Procurement Promotion Association of China discussed practical pathways for the internationalization of Chinese assets. Meanwhile, Guotai Haitong Securities Investment, Huangfeng Capital, and AllBright Law Offices focused their discussions on cross-border business development (BD) practices in the medical device sector.

Overall, the main forum includesTipping Points in Trends, Optimal Solutions Below the Tipping Point, and Development Opportunities Beneath ItThree Major Segments: Guests from the Six Circles of Government, Industry, Academia, Research, Healthcare, and Investment Observe Macro Trends and Focus on Micro Practices to Discuss Growth Engines in China’s Healthcare Industry and Precisely Identify High-Quality Asset Growth Points.

Concurrent N+ Events: Premium Assets + High-Quality Buyers, Building a Global Trading Network for Chinese Assets

Welcome Industry Partners to Register, engage in direct communication and partnership negotiations with innovative enterprises.